Can diltiazem be used to treat paroxysmal supraventricular tachycardia?

Can Diltiazem Be Used in PSVT?

Yes, diltiazem is highly effective for treating paroxysmal supraventricular tachycardia (PSVT) and is recommended as a Class IIa intervention by the American Heart Association for both acute termination and ongoing management of hemodynamically stable PSVT. 1

Acute Treatment of PSVT

When to Use Diltiazem

Diltiazem is indicated as second-line therapy when adenosine or vagal maneuvers fail to convert PSVT, when PSVT recurs after initial treatment, or when these initial treatments reveal another form of SVT requiring sustained rate control. 1

The FDA specifically approves intravenous diltiazem for rapid conversion of PSVT to sinus rhythm, including AV nodal reentrant tachycardias and reciprocating tachycardias associated with accessory pathways such as Wolff-Parkinson-White syndrome. 2

Efficacy Data

• Conversion rates: 64-98% of hemodynamically stable PSVT patients convert to normal sinus rhythm with IV diltiazem 1
• Time to conversion: Median 2-3 minutes after initiation of infusion 3, 4
• Success by mechanism: 100% for AV nodal reentrant tachycardia and 81% for AV reciprocating tachycardia 4
• Comparative effectiveness: Diltiazem achieved 95% conversion rate versus only 25% with adenosine in one study 5

Dosing Protocol

Initial dose: 15-20 mg (0.25 mg/kg) IV over 2 minutes 1

If no response after 15 minutes:

• Second dose: 20-25 mg (0.35 mg/kg) IV over 2 minutes 1
• Maintenance infusion: 5-15 mg/hour, titrated to heart rate 1

The FDA label specifies that response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2-7 minutes. 2

Critical Safety Considerations

Absolute Contraindications

Do NOT use diltiazem in the following situations:

• Pre-excited atrial fibrillation or flutter (may accelerate ventricular response and precipitate ventricular fibrillation) 1
• Wide-complex tachycardia of unknown etiology (may be ventricular tachycardia) 1
• Hemodynamically unstable patients (hypotension, cardiogenic shock, acute decompensated heart failure) 1
• AV block greater than first degree or SA node dysfunction without a pacemaker 1
• Decompensated systolic heart failure or significant LV dysfunction 1

Important Precautions

• Ensure narrow-complex tachycardia: Diltiazem should only be given to patients with narrow-complex reentry SVT or arrhythmias known with certainty to be supraventricular in origin 1
• Avoid sequential AV nodal blockers: Do not combine diltiazem with other longer-acting AV nodal blocking agents (beta-blockers, verapamil) as profound bradycardia can develop 1
• Monitor continuously: Setting should include continuous ECG monitoring, frequent blood pressure measurement, and readily available defibrillator 2

Adverse Effects

• Hypotension is the most common adverse effect (occurring in approximately 7% of patients), though only 4% require intervention 1, 3
• Bradycardia may occur 1
• Worsening heart failure in patients with pre-existing ventricular dysfunction (rare) 2

Ongoing Management

For long-term prophylaxis, oral diltiazem is a Class I recommendation for symptomatic PSVT patients without ventricular pre-excitation. 1

Oral diltiazem is particularly appropriate for patients who:

• Prefer not to undergo catheter ablation 1
• Do not have access to a cardiac electrophysiologist 1
• Have infrequent but prolonged episodes 1

Alternative: Single-Dose "Pill-in-the-Pocket" Approach

Diltiazem 120 mg plus propranolol 80 mg as a single oral dose has been shown superior to placebo for terminating acute PSVT episodes in patients with infrequent but prolonged episodes. 1 This approach is appropriate for patients free of significant LV dysfunction, sinus bradycardia, or pre-excitation. 1

Comparison with Other Agents

Adenosine remains first-line for acute PSVT due to its rapid action and shorter side-effect profile 1, but diltiazem offers several advantages:

• Longer duration of action provides more sustained termination and rate control 1
• Higher conversion rates in some studies (95% vs 25% for adenosine) 5
• Useful after adenosine failure or recurrence 1
• Better tolerated than esmolol (95% vs 25% efficacy) 6

Verapamil has similar efficacy to diltiazem (both 64-98% conversion rates), but diltiazem may have a slightly better safety profile with less hypotension when infused slowly over 20 minutes. 1, 7

Clinical Pearls

• If the first bolus fails, give a second bolus: In one study, 13 of 28 patients who responded to diltiazem required the second bolus after the first failed 6
• Slow infusion reduces hypotension risk: Infusing over up to 20 minutes may lessen the potential for hypotension 1
• ECG clues favor diltiazem: Presence of visible retrograde P waves or aVL notch on ECG may predict better response to diltiazem than adenosine 5
• Pregnancy considerations: While evidence is limited, diltiazem may be used with caution in pregnant women without WPW syndrome after the first trimester 1